Extends over-the-counter drug review fees through 2030

Bill s2292-119 ("Extends over-the-counter drug review fees through 2030") is before Congress and has not been decided. Latest step (September 8, 2025): Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.

Congress file s2292-119, before Congress. No action in 435 days as of 2025-09-08.

What it does

Drug companies pay fees to speed up OTC approvals Companies making over-the-counter drugs will pay annual fees through 2030 to fund FDA reviewers who evaluate new nonprescription products and switch prescription drugs to OTC status.

The bigger picture

Faster OTC approval process brings more drugs to shelves With dedicated funding, the FDA can review applications to move prescription drugs to nonprescription status more quickly, potentially bringing medications like pain relievers and allergy drugs to store shelves sooner.

Official summary

This bill reauthorizes the Over-the-Counter (OTC) Monograph Drug User Fee Program (OMUFA); revises procedures used by the Food and Drug Administration (FDA) to evaluate topical, nonprescription drugs (e.g., sunscreens); and requires the FDA to clarify the process through which a prescription drug may be switched to nonprescription status.Under current law, many OTC drugs are marketed through compliance with an OTC monograph issued by the FDA, rather than through an approved new drug application. Monographs establish the conditions under which OTC drugs are generally recognized as safe and effective. The bill reauthorizes the collection of OMUFA fees from OTC drug facilities through FY2030 and revises methods for calculating such fees.Separately, the bill requires the FDA to allow for the use of real-world evidence to demonstrate the safety and effectiveness of active ingredients in topical, nonprescription drugs. The FDA must consider nonclinical tests and other alternatives to animal testing in evaluating such drugs.The FDA must also issue guidance to clarify the application process for nonprescription drugs, including applications to switch a prescription drug to nonprescription

Read the official record for s2292-119

See everything up for a vote · This week in Congress · See what we have filed with the clerk